In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Insulet’s current price of $145.76 exceeds the PERT-weighted fair value of $118.78, indicating overvaluation by 18.5%. Divergence among valuation methods, notably negative DCF versus high analyst targets, reveals conflicting expectations. Strong financial health and zero downside risk in Monte Carlo analysis support stability despite valuation headwinds.